Gluten-Free Diet in IBD: Time for a Recommendation?
Study Goal
The researchers aimed to evaluate the therapeutic efficacy of gluten-free or low-gluten diets in managing inflammatory bowel diseases (IBD) by examining clinical associations with celiac disease and non-celiac gluten sensitivity.
Results Summary
The study found no prospective evidence supporting the universal use of a gluten-free diet (GFD) for IBD, though cross-sectional reports suggest symptom improvement in some patients. Animal studies indicate gluten may promote intestinal inflammation, but human clinical data are lacking.
Population
Patients with inflammatory bowel diseases (IBD), including Crohn's disease and ulcerative colitis, as well as those with celiac disease (CeD) or non-celiac gluten sensitivity (NCGS).
Effective Dosage
Not specified
Duration
Not specified
Interactions
None mentioned
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
gluten-free diet (GFD) | decrease | symptoms | IBD patients | - | may improve symptoms | #1 |
gluten ingestion | increase | intestinal inflammation | - | - | may promote | #2 |
gluten ingestion | increase | intestinal permeability | - | - | increase | #3 |
gluten-free diet (GFD) | no change | induction and maintenance of Crohn's disease and ulcerative colitis | - | no prospective studies | no prospective studies evaluating the role | #4 |
gluten-free diet (GFD) | no change | use in IBD | IBD patients | - | current data do not support the universal use | #5 |
Patients and providers alike are highly interested in identifying potentially useful dietary interventions in the management of inflammatory bowel diseases (IBD). This review examines the clinical associations of celiac disease (CeD), non-celiac gluten sensitivity (NCGS), and IBD with a focus on available data of the therapeutic efficacy of gluten-free diet (GFD) or low-gluten-containing diets in the therapy of IBD. There is a strong association between CeD and microscopic colitis, but the prevalence of CeD among IBD patients is similar to that of the general population. Interestingly, in cross-sectional studies nearly one-third of IBD patients report a diagnosis of NCGS, and many follow a GFD. Although animal studies have shown that gluten ingestion may promote intestinal inflammation and increase intestinal permeability, there have been no prospective studies evaluating the role of a GFD in the induction and maintenance of Crohn's disease and ulcerative colitis. Several cross-sectional reports suggest that a GFD may improve symptoms in IBD patients, but due to a lack of high-quality prospective clinical studies, current data do not support the universal use of a GFD in IBD.